ライフサイエンスコーパス: fluorouracil

1 platin, leucovorin, and bolus and infusional fluorouracil).

2 aliplatin and irinotecan plus leucovorin and fluorouracil).

3 available anti-cancer drugs (imiquimod and 5-fluorouracil).

4 nt cetuximab and two cycles of cisplatin and fluorouracil.

5 tive effects of a standard course of topical fluorouracil.

6 ant p53-expressing cell lines resistant to 5-fluorouracil.

7 e colorectal cancer chemotherapeutic agent 5-fluorouracil.

8 into immunodeficient mice was inhibited by 5-fluorouracil.

9 gents, including cisplatin, sorafenib, and 5-fluorouracil.

10 sensitizes tumour cells to doxorubicin and 5-Fluorouracil.

11 ated apoptosis-inducing ligand (TRAIL) and 5-fluorouracil.

12 easing UBE2C expression in the presence of 5-fluorouracil.

13 agents, namely, cisplatin, docetaxel, and 5-fluorouracil.

14 injury induced by serial administration of 5-fluorouracil.

15 ide analogs, ribavirin, 5-azacytidine, and 5-fluorouracil.

16 ate, photodynamic therapy, colchicine, and 5-fluorouracil.

17 ediate for oxaliplatin and the largest for 5-fluorouracil.

18 cancer cells to the chemotherapeutic agent 5-fluorouracil.

19 5-Fluorouracil 1% administered topically 4 times daily for

20 We assessed the effect of fluorouracil 1% eye drops after surgery on recurrence.

21 randomly allocated to receive either topical fluorouracil 1% or placebo four times a day for 4 weeks.

22 atin [80 mg/m(2) intravenously on day 1] and fluorouracil [1 g/m(2) per day intravenously on days 1-4

23 ron emission tomography (PET) agent [(18)F]5-fluorouracil ([(18)F]FU).

24 re randomly assigned to receive either mDCF (fluorouracil 2,000 mg/m2 intravenously [IV] over 48 hour

25 All patients received chemoradiation (fluorouracil 225 mg/m(2) per day by continuous infusion

26 y over 5 min, followed by a 46 h infusion of fluorouracil 2400 mg/m(2) repeated every 2 weeks (regime

27 400 mg/m(2) on day 1, and a 46-h infusion of fluorouracil 2400 mg/m(2).

28 LFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48

29 as performed on COLO205 cells treated with 5-fluorouracil (3.1, 31, or 310 muM) and oxaliplatin (0.7

30 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400 mg/m(2) bolus followed by 2400 mg/m(2)

31 liplatin 85 mg/m(2) in a 2-h infusion, bolus fluorouracil 400 mg/m(2) on day 1, and a 46-h infusion o

32 0 mg/m(2), leucovorin 400 mg/m(2), and bolus fluorouracil 400 mg/m(2), followed by 2400 mg/m(2) 46-h

33 drugs or drug combination, indicating that 5-fluorouracil (5-FU) + irinotecan (IRI) + bevacizumab (BE

34 uate AUY922, alone and in combination with 5-fluorouracil (5-FU) and cisplatin.

35 5-Fluorouracil (5-FU) and its metabolite 5-fluorodeoxyurid

36 ion stress-inducing chemotherapies such as 5-Fluorouracil (5-FU) and methotrexate (MTX) leading to en

37 ctively potentiated cytotoxicity of SN-38, 5-fluorouracil (5-FU) and mitoxantrone, but not that of ge

38 the protected analogues of cytotoxic drugs 5-fluorouracil (5-FU) and monomethyl auristatin E (MMAE) a

39 gued that colorectal cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such effects,

40 s to unrestricted myelopoietic response to 5-fluorouracil (5-FU) and, in turn, induces exhaustion of

41 topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic kera

42 proliferation via a chemotherapeutic agent 5-fluorouracil (5-Fu) eliminated fast-cycling stem cells,

43 etion of Bok results in chemoresistance to 5-fluorouracil (5-FU) in different cell lines and in mice.

44 Moreover, the combination of CB-839 and 5-fluorouracil (5-FU) induces PIK3CA-mutant tumor regressi

45 5-Fluorouracil (5-FU) is a chemotherapeutic drug widely us

46 5-Fluorouracil (5-FU) is a standard treatment option for c

47 5-Fluorouracil (5-FU) is an anticancer agent whose main si

48 cular mode of action of the cytotoxic drug 5-fluorouracil (5-FU) is generally considered to result fr

49 The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used chemo

50 ugh colorectal cancer (CRC) treatment with 5-fluorouracil (5-FU) is the first line of therapy for thi

51 ly monitor the effect of the anticancer drug fluorouracil (5-FU) on HCT116 cancer spheroids.

52 ensitive to treatment with the RNA mutagen 5-fluorouracil (5-FU) than wild-type (WT)-ExoN(+), suggest

53 these NPs-treated cancer cells compared to 5-fluorouracil (5-FU) treated cells.

54 Furthermore, cellular stress triggered by 5-fluorouracil (5-FU) treatment potentiates the effects of

55 pecies using three chemotherapeutic drugs: 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FUDR), an

56 Standard therapies such as gemcitabine, 5-fluorouracil (5-FU), doxorubicin and gamma-irradiation d

57 n cancer recurrence after therapy, such as 5-fluorouracil (5-FU), remains a challenge in the clinical

58 unctionalised with Rose Bengal (RB) and/or 5-fluorouracil (5-FU), were assessed as a delivery vehicle

59 ession of miR-520g conferred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in

60 Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (

61 with dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-intercalated nanobeacons that serve

62 o 5-FU for >100 passages, we established a 5-fluorouracil (5-FU)-tolerant line, MKN45/5FU.

63 ect on pharmacokinetics of and response to 5-fluorouracil (5-FU).

64 umor necrosis factor alpha (TNF-alpha) and 5-Fluorouracil (5-FU).

65 tions conferring resistance to the mutagen 5-fluorouracil (5-FU): nsp12-M611F and nsp12-V553I.

66 Initially, 5-Fluorouracil(5-FU)/Belotecan/Oxaliplatinum and Tegafur/G

67 To investigate the effect of topical fluorouracil, 5%, cream on photoaging using validated ph

68 articipants were randomized to apply topical fluorouracil, 5%, cream or a vehicle control cream to th

69 photoaging with a standard course of topical fluorouracil, 5%, cream, a finding that may be attributa

70 e every 21 days) followed by three cycles of fluorouracil (500 mg/m(2)), epirubicin (100 mg/m(2)), an

71 (75 mg/m(2) on day 1 of cycles 1-4) and FEC (fluorouracil [500 mg/m(2)], epirubicin [75 mg/m(2)], and

72 s a prodrug, which is converted into toxic 5-fluorouracil (5FU) upon uptake into fungal cells.

73 gery, patients received three cycles of FEC (fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), and cyc

74 ren <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m(2) per dose or 20 mg/kg per dose

75 ificantly higher among patients who received fluorouracil (74.7%; 95% confidence interval [CI], 66.8

76 (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte c

77 reased cell viability when co-incubated with fluorouracil (77.1% vs 46.6%, p=0.037) and irinotecan (4

78 y at clinician's discretion) and intravenous fluorouracil 800 mg/m(2) per day on days 1-4 of radiothe

79 5-Fluorouracil (800 mg/m(2) intravenous infusion on days 1

80 eks followed by 1 week off (or intravenous 5-fluorouracil, 800 mg/m(2) per day on days 1-5), and a 20

81 treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively.

82 dose (23%; P = .64) and by similar systemic fluorouracil (active drug) exposure.

83 s were identified between grade 3 or greater fluorouracil AEs and both D949V (odds ratio [OR], 6.3 [9

84 2I with the occurrence of grade 3 or greater fluorouracil AEs and overall hematologic adverse events

85 The incidence of grade 3 or greater fluorouracil AEs in D949V and V732I (DPYD*6) carriers wa

86 nd increased incidence of grade 3 or greater fluorouracil AEs in patients treated with adjuvant fluor

87 To determine the impact of DPYD variants on fluorouracil AEs in patients with stage III CC treated w

88 ants on fluorouracil-related adverse events (fluorouracil AEs).

89 een each DPYD variant and grade 3 or greater fluorouracil AEs.

90 Topical fluorouracil after surgery substantially reduced recurre

91 cell lines BON1 and QGP1 were treated with 5-fluorouracil alone or in combination with decitabine or

92 : This preclinical study demonstrated that 5-fluorouracil alone or in combination with decitabine or

93 Results: Treatment with 5-fluorouracil alone or in combination with decitabine or

94 Mutants sensitive to 5-fluorouracil, an anticancer drug are under-represented w

95 d July, 2014, we assigned 49 participants to fluorouracil and 49 to placebo.

96 owing treatment with the anticancer agents 5-fluorouracil and 5-fluorodeoxyuridine (floxuridine), a 5

97 initial therapy to maintenance chemotherapy (fluorouracil and cisplatin) or no maintenance chemothera

98 er participant was not different between the fluorouracil and control groups at randomization (11.1 v

99 ndard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 wee

100 l irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4

101 95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI

102 ssigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal iri

103 liposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149).

104 alent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added la

105 Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a ma

106 oliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this

107 ients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8

108 ients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]

109 valent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid.

110 We focused on 5-Fluorouracil and Gemcitabine because based on our exclus

111 ly or negatively to two chemotherapeutics: 5-Fluorouracil and Gemcitabine.

112 hich cancer patients received oxaliplatin, 5-fluorouracil and irinotecan via chronomodulated schedule

113 ding explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of

114 ctively potentiated cytotoxicity of SN-38, 5-fluorouracil and mitoxantrone, but not that of gemcitabi

115 Bacterial conversion of 5-FC to 5-fluorouracil and subsequently to fluorouridine monophosp

116 emonstrate survival superiority is platinum, fluorouracil, and cetuximab, a monoclonal antibody direc

117 4 had increased resistance to gemcitabine, 5-fluorouracil, and cisplatin, whereas AsPC-1 cells with Z

118 received full-dose radiotherapy, concomitant fluorouracil, and concomitant oxaliplatin in groups A an

119 6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superi

120 ich different combinations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metas

121 nation with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal

122 ation chemotherapy, FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D printed fluidic de

123 ve been treated with combination leucovorin, fluorouracil, and oxaliplatin (FOLFOX)-based adjuvant ch

124 evacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the

125 t FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or with

126 atin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plus single tre

127 III SCCAC received CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor

128 e chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control

129 nts received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resectio

130 -surgery, with the combination of cisplatin, fluorouracil, and vincristine.

131 ith CMF (cyclophosphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast

132 MT, invasion, migration, and resistance to 5-fluorouracil, as well as metastasis of xenograft tumors

133 opical corticosteroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with i

134 C) plus local chemotherapy (cisplatin and 5-fluorouracil), (b) chemotherapy alone, (c) RF hypertherm

135 tients with stage III/IV PDAC treated with 5-fluorouracil based therapy (n = 176).

136 -defined high-risk stage II CRC who received fluorouracil-based adjuvant chemotherapy showed a substa

137 6 patients in 3 independent cohorts received fluorouracil-based adjuvant chemotherapy.

138 disease who could gain survival benefit from fluorouracil-based adjuvant chemotherapy.

139 ould gain substantial survival benefits from fluorouracil-based adjuvant chemotherapy.

140 Overall, adjuvant fluorouracil-based chemotherapy did not improve overall

141 ention of oral mucositis in adults receiving fluorouracil-based chemotherapy for solid cancers, and f

142 The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care fo

143 them predicted histopathological response to fluorouracil-based chemotherapy regimens, of which the F

144 uracil AEs in patients treated with adjuvant fluorouracil-based combination chemotherapy.

145 ectal cancer is preoperative, long course (5-fluorouracil-based) CRT.

146 se administered intravenously over 2 h), and fluorouracil bolus 400 mg/m(2) administered intravenousl

147 DNA-damaging agents (i.e., oxaliplatin and 5-fluorouracil), but not with PARPi therapy.

148 in patients treated with fluoropyrimidines (fluorouracil, capecitabine, or tegafur-uracil as single

149 ective of intratumoural transport, including fluorouracil, carmustine, cisplatin, methotrexate, doxor

150 therapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy).

151 tage, to receive two cycles of cisplatin and fluorouracil (CF; two 3-weekly cycles of cisplatin [80 m

152 hed perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for pati

153 or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Counci

154 hematologic recovery in mice treated with 5-fluorouracil chemotherapy.

155 Furthermore, they are safer compared to 5-fluorouracil, cisplatin and betulinic acid on NIH/3T3, C

156 a and planned neoadjuvant chemoradiation (5- fluorouracil, cisplatin, 40Gy) followed by 2-field trans

157 classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m(2) cyclophosphamide intraven

158 le actinic keratosis lesions on the head, 5% fluorouracil cream was the most effective of four field-

159 Participants applied either topical fluorouracil cream, 5% (n = 468), or vehicle control cre

160 were randomly assigned to treatment with 5% fluorouracil cream, 5% imiquimod cream, methyl aminolevu

161 Our results indicate that a single course of fluorouracil cream, 5%, effectively reduces AK counts an

162 Most patients receiving intravenous 5-fluorouracil develop side effects.

163 ng CSCs with a genotoxic drug combination (5-fluorouracil, doxorubicin, and cyclophosphamide) generat

164 irubicin, cisplatin, and continuous-infusion fluorouracil (ECF), irinotecan plus cisplatin (IC), or F

165 lanned cancer treatment was 3 cycles of FEC (fluorouracil, epirubicin [100 mg/m(2) per dose], and cyc

166 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

167 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

168 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

169 apeutic drugs that activate p53, including 5-fluorouracil, etoposide and cisplatin.

170 TRMT2A-tRNA crosslinking in vivo following 5-Fluorouracil exposure is also intriguing, as it suggests

171 FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and

172 therapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and

173 urvival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected panc

174 of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (

175 mg infusion over 2 h, and 400 mg/m(2) bolus fluorouracil followed by a 2400 mg/m(2) continuous fluor

176 h, 200 mg leucovorin, and 400 mg/m(2) bolus fluorouracil followed by a 2400 mg/m(2) continuous fluor

177 eceive three cycles of IC with cisplatin and fluorouracil, followed by CCR with three cycles of cispl

178 leucovorin calcium, and then 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of exte

179 ctide-co-glycolide), polycaprolactone, and 5-fluorouracil for delivering the anti-cancer drug in a pr

180 Spheroids were treated with 5-Fluorouracil for five days through continuous perfusion

181 etinoic acid, dexamethasone, doxorubicin, 5'-fluorouracil, forskolin), sodium dodecyl sulfate (+contr

182 d postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surg

183 reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the oxaliplatin,

184 d a general higher sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX

185 The fluorouracil group also had higher complete AK clearance

186 occurred in five (11%) of 47 patients in the fluorouracil group and 17 (36%) of 47 in the placebo gro

187 ugh there were fewer hypertrophic AKs in the fluorouracil group at 6 months (0.23 vs 0.41) (P = .05).

188 After randomization, the fluorouracil group had fewer AKs compared with the contr

189 The fluorouracil group took longer to require the first spot

190 comfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group,

191 dverse effects occurred more commonly in the fluorouracil group, although they were transient and mil

192 ucleoside analogues, such as ribavirin and 5-fluorouracil, have been ineffective at inhibiting CoVs.

193 Gemcitabine, 5-fluorouracil, hydroxyurea, doxorubicin and paclitaxel ha

194 when cell proliferation was suppressed with fluorouracil in apolipoprotein E knock out mice (P<0.05)

195 apy, yet development of drug resistance to 5-fluorouracil in colorectal cancer cells is the primary c

196 reclinical in vitro findings indicate that 5-fluorouracil in combination with epigenetic modifiers mi

197 ing oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastatic pancreatic can

198 re than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.

199 a albicans infection and more sensitive to 5-fluorouracil-induced granulocytic regeneration.

200 single-nucleotide resolution mapping method, Fluorouracil-Induced-Catalytic-Crosslinking-Sequencing (

201 uracil followed by a 2400 mg/m(2) continuous fluorouracil infusion over 46 h).

202 uracil followed by a 2400 mg/m(2) continuous fluorouracil infusion over 46 h).

203 recovery after sub-lethal irradiation and 5-fluorouracil injection.

204 Subconjunctival 5-fluorouracil injections were given postoperatively, as n

205 was also exacerbated by stress induced by 5-fluorouracil injections.

206 travenously on days 1 and 8; and 600 mg/m(2) fluorouracil intravenously on days 1 and 8 of each cycle

207 l trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin

208 herapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX),

209 nstream gene-targets, and interaction with 5-fluorouracil, irinotecan, and oxaliplatin.

210 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable com

211 nd safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for

212 s tumour regeneration after treatment with 5-fluorouracil is blocked.

213 5-Fluorouracil is effective and well tolerated as a primar

214 We developed fluorouracil-labeled RNA sequencing (Flura-seq) for in s

215 of UNG, catalyzes the removal of uracil or 5-fluorouracil lesions that accumulate in DNA following tr

216 wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus

217 wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus

218 y demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) signi

219 fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line t

220 b in the first-line treatment and subsequent fluorouracil, leucovorin, and irinotecan with or without

221 ermine a preferred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epiru

222 assigned to 3 months or 6 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) every

223 he efficacy of a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versu

224 ng yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based

225 in patients with stage III CC treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regi

226 induction chemotherapy using three cycles of fluorouracil, leucovorin, and oxaliplatin before fluorou

227 8737) investigating the duration of adjuvant fluorouracil, leucovorin, and oxaliplatin or capecitabin

228 on of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouraci

229 els to compare the cost and effectiveness of fluorouracil, leucovorin, and oxaliplatin with or withou

230 uated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08C

231 ed as modified FOLFOX6 (mFOLFOX6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusi

232 ding relaxin (RLN), FOLFOX (combination of 5-fluorouracil, leucovorin, and oxaliplatin), and IL-12, s

233 ect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer ov

234 patients with resectable disease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mF

235 14.9 months for those receiving induction 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (F

236 The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (m

237 s recommended in the metastatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin an

238 stration that cytotoxic combinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as

239 utic regimen FOL-F-IRIN-OX (combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) o

240 s in arm A received 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FL

241 Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) tr

242 verall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (F

243 lticenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Col

244 d to preoperative epirubicin, cisplatin, and fluorouracil may be appropriate.

245 previously suspected RNA-dependent route of Fluorouracil-mediated cytotoxicity.

246 deaminase (CD) to convert fluorocytosine to fluorouracil, metabolically labeling nascent RNA in rare

247 and 5-fluorodeoxyuridine (floxuridine), a 5-fluorouracil metabolite.

248 5-fluorouracil, often given with leucovorin, is the most c

249 (the active metabolite of irinotecan) and 5-fluorouracil on cell proliferation under hypoxic conditi

250 Effect of a standard course of fluorouracil on the extent of photodamage as measured us

251 mg/m(2) on days 1 and 29), with intravenous fluorouracil (one dose of 1000 mg/m(2) per day on days 1

252 rectum who had received RCT (45-50 Gy with 5-fluorouracil or capecitabine) were included and randomiz

253 ectum who had received RCT (45 to 50 Gy with fluorouracil or capecitabine) were included.

254 f either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or cap

255 281 participants randomized to apply topical fluorouracil or placebo were evaluated at baseline, 6 mo

256 ects are observed in feathers treated with 5-fluorouracil or taxol but not with doxorubicin or arabin

257 ith an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor (erlotinib),

258 laucoma incisional surgery, intraoperative 5-fluorouracil, or follow-up <1 month.

259 ubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treat

260 The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizum

261 rouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy) or to group B for

262 ion with chemotherapy [C26 oxaliplatin and 5-fluorouracil (oxfu)] and to evaluate the potential of mo

263 b alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetux

264 Fluorouracil plus cisplatin and radiation twice a day (F

265 ternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered.

266 chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patient

267 Fluorouracil plus leucovorin (FU + LV) adjuvant chemothe

268 rs, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus ox

269 s oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]).

270 aliplatin (IROX) compared with those given 5-fluorouracil plus oxaliplatin (FOLFOX; cycle 1 mean grad

271 0 to 1, and a favorable comorbidity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposo

272 clinical study, we explored the effects of 5-fluorouracil plus the DNA methyltransferase inhibitor de

273 acy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy.

274 midine dehydrogenase gene (DPYD) variants on fluorouracil-related adverse events (fluorouracil AEs).

275 nd reduced the viability of self-renewing, 5-fluorouracil-resistant Aldefluor positive [Aldefluor(+)]

276 onosphere formation of unsorted and sorted 5-fluorouracil-resistant CSCs.

277 5-Fluorouracil-resistant TYMS T51S, G52S (TYMS(SS)) is res

278 e-rifampicin (RR, 0.14 [95% CI, .05-.36]), 5-fluorouracil (RR, 0.34 [95% CI, .14-.82]), and chlorhexi

279 able comorbidity profile, and gemcitabine or fluorouracil should be offered to patients with either a

280 reased response to the nucleoside analogue 5-fluorouracil, suggesting that lower levels of this methy

281 fractions during 5.5 weeks, with infusion 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of

282 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other half received 3 cy

283 icantly enriched in patients pretreated with fluorouracil, taxanes, platinum and/or eribulin, whereas

284 Novel conjugates of ferrocene with uracil, 5-fluorouracil, tegafur, or acyclovir are reported.

285 mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the WT virus, whereas the lower-fideli

286 As compared with fluorouracil, the hazard ratio for treatment failure was

287 zed targeted CONs for targeted delivery of 5-fluorouracil to breast cancer cells.

288 cil) degradation metabolites in predicting 5-fluorouracil toxicity and the role of the agmatine pathw

289 es were collected from 53 stage II and 54 (5-fluorouracil-treated) stage III patients.

290 Only upon 5-fluorouracil treatment was HSPC-depleted bone marrow com

291 dac8-deficient mice challenged with serial 5-fluorouracil treatment.

292 SC more vulnerable to serial myeloablative 5-fluorouracil treatment.

293 mice are significantly more susceptible to 5-fluorouracil treatment.

294 graft tumor initiation and was superior to 5-fluorouracil treatment.

295 es PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions.

296 In mice treated with topical 5-fluorouracil, use of STAR particles increased the effica

297 f VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresp

298 Topical fluorouracil was demonstrated to be effective in reducin

299 e were given intraperitoneal injections of 5-fluorouracil, which blocked gastric cell proliferation,

300 SJSA cells treated with 5-fluorouracil, which induces metabolic and genotoxic stre